ArticleNature communications2023
CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- A systematic review and meta-analysis of metalloproteinases in patients with Alzheimer's disease and mild cognitive impairment.Journal of Alzheimer's disease : JAD · 2026Pooled it
- Systematic review of differentially abundant proteins in people with Lewy body dementia.Acta neuropsychiatrica · 2025Pooled it
- Effects of the novel phosphodiesterase 9 inhibitor irsenontrine on CSF proteomics profile in AβAlzheimer's research & therapy · 2026Trial
- Serum aromatic l-amino acid decarboxylase activity as a biomarker for prodromal and manifest Parkinson's disease.EBioMedicine · 2026Article
- Metabolism Pathway Blood Proteomic Differences in Lewy Body Dementia Compared to Alzheimer's Disease.International journal of molecular sciences · 2026Article
- Article
- Analytical and clinical validation of a novel proximity extension assay-based plasma biomarker panel in a cohort of prevalent neurodegenerative dementias.Alzheimer's research & therapy · 2026Article
- Patient cerebral organoids capture Alzheimer's disease proteomic biomarkers and drug targets.bioRxiv : the preprint server for biology · 2026Article
- Myelin damage in donor skin differentiates between synucleinopathies.NPJ Parkinson's disease · 2026Article
- Review
- A monoclonal antibody-based immunoassay reinforces DOPA decarboxylase in cerebrospinal fluid as a diagnostic biomarker for Parkinson's disease with potential prognostic value.Journal of Parkinson's disease · 2026Article
- Towards biomarker-based diagnosis of Parkinson disease.Nature reviews. Neurology · 2026Review
- DOPA decarboxylase levels in the cerebrospinal fluid as a diagnostic marker of Lewy body disorders.Nature medicine · 2026Article
- High Cerebrospinal DOPA Decarboxylase Level Predicts Cognitive Decline in Parkinson's Disease.Movement disorders clinical practice · 2026Article
- Understanding Neurodegenerative Diseases From the -Omics Perspective: Lessons Learnt.Annals of neurology · 2026Review
- A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders.Nature medicine · 2026Article
- Identification of distinct and shared biomarker panels in different manifestations of cerebral small-vessel disease through proteomic profiling.Nature aging · 2026Article
- Article
- Development and validation of a novel panel of CSF biomarkers for Alzheimer's disease.Alzheimer's research & therapy · 2026Article
- Multi-platform integration of brain and CSF proteomes reveals biomarker panels for Alzheimer's disease.Briefings in bioinformatics · 2026Article
Corrections and comments
- Commented on by
Authors and funding
16 authors at 8 institutions in 4 countries.
Funding
Abstract
Diagnosis of dementia with Lewy bodies (DLB) is challenging and specific biofluid biomarkers are highly needed. We employed proximity extension-based assays to measure 665 proteins in the cerebrospinal fluid (CSF) from patients with DLB (n = 109), Alzheimer´s disease (AD, n = 235) and cognitively unimpaired controls (n = 190). We identified over 50 CSF proteins dysregulated in DLB, enriched in myelination processes among others. The dopamine biosynthesis enzyme DDC was the strongest dysregulated protein, and could efficiently discriminate DLB from controls and AD (AUC:0.91 and 0.81 respectively). Classification modeling unveiled a 7-CSF biomarker panel that better discriminate DLB from AD (AUC:0.93). A custom multiplex panel for six of these markers (DDC, CRH, MMP-3, ABL1, MMP-10, THOP1) was developed and validated in independent cohorts, including an AD and DLB autopsy cohort. This DLB CSF proteome study identifies DLB-specific protein changes and translates these findings to a practicable biomarker panel that accurately identifies DLB patients, providing promising diagnostic and clinical trial testing opportunities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.